VEEV VEEVA SYSTEMS INC
Price Chart
Executive Summary
Veeva reported FQ1 2027 results that exceeded guidance on all metrics: total revenue of $882.9M (+16% YoY) and GAAP diluted EPS of $1.57, beating the $2.24 consensus on a non-GAAP basis. The company raised its full-year FY2027 revenue guidance to $3,635-$3,645M (from $3,585-$3,600M) and non-GAAP EPS guidance to ~$9.05 (from ~$8.85), signaling accelerating momentum in its life sciences cloud business.
Key Financial Metrics
Actionable Insight
The raised full-year guidance and accelerating subscription growth (+15% YoY) confirm durable demand in life sciences cloud. Watch for continued Vault CRM adoption and AI agent monetization as catalysts. The stock may gap up on the beat-and-raise; consider taking profits if the move exceeds 5-7% intraday given the stock's historical volatility post-earnings.
Key Facts
- Total revenues of $882.9M, up 16% YoY, above the $888.6M consensus (beat by 0.1%)
- Subscription revenues of $730.2M, up 15% YoY, driven by R&D and Quality Solutions ($392.3M, +19% YoY)
- GAAP diluted EPS of $1.57 vs $1.37 a year ago; non-GAAP diluted EPS of $2.24, in line with consensus
- Raised FY2027 revenue guidance to $3,635-$3,645M (from $3,585-$3,600M) and non-GAAP EPS to ~$9.05 (from ~$8.85)
- Q2 FY2027 guidance: revenue $902-$905M, non-GAAP EPS $2.21-$2.22
- Operating cash flow of $1.13B in the quarter, up 28% YoY
- Added 27 new Vault CRM customers in the quarter, now over 150 live; AI strategy advancing with Ostro, Vault AI, and Veeva Falcon
Financial Impact
Revenue beat by ~$0.3M vs consensus; raised FY guidance by ~$50M; non-GAAP EPS guidance raised by ~$0.20
Risk Factors
- Macroeconomic headwinds could slow biopharma IT spending
- Execution risk on AI agent rollout (Veeva Falcon, Vault AI) and customer adoption timelines
- Competition from Salesforce and other cloud vendors in life sciences vertical
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001393052-26-000022 |
| Document: veev-20260603.htm | 0001393052-26-000022 |
| Document: 0001393052-26-000022-index-headers.html | 0001393052-26-000022 |
| Document: 0001393052-26-000022-index.html | 0001393052-26-000022 |
| Document: 0001393052-26-000022.txt | 0001393052-26-000022 |
| 8-K Data (Synthetic) | 0001393052-26-000022 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
11d ago
|
8-K
| $178.54 $172.61 | ▼ −3.32% | ▼ −0.75% | $159.54 (−10.64%) |
|
May 4, 2026
5w ago
|
DEFA14A
| $170.18 $170.66 | ▲ +0.28% | ▼ −0.51% | $159.54 (−6.25%) |
|
Apr 20, 2026
7w ago
|
8-K
| $167.71 $162.94 | ▼ −2.84% | ▼ −3.86% | $159.54 (−4.87%) |
|
Mar 4, 2026
14w ago
|
8-K
| $195.27 $194.87 | ▼ −0.20% | ▲ +1.11% | $159.54 (−18.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access